Kaposi's sarcoma - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Kaposi’s sarcoma – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Kaposi’s sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Kaposi’s sarcoma: Overview
Kaposi sarcoma, also called idiopathic multiple pigmented hemorrhagic sarcoma, rare and usually lethal cancer of the tissues beneath the surface of the skin or of the mucous membranes. The disease can spread to other organs, including the liver, lungs, and intestinal tract. Kaposi sarcoma is characterized by red-purple or blue-brown lesions of the skin, mucous membranes, and other organs. Kaposi sarcoma originates from endothelial cells in response to infection by human herpesvirus type 8 (HHV-8). Immunosuppression (particularly by AIDS and drugs for organ transplant recipients) markedly increases the likelihood of Kaposi sarcoma in HHV-8–infected patients. KS is categorized into the following 4 types: Classic Kaposi sarcoma, AIDS-associated Kaposi sarcoma, Endemic Kaposi sarcoma, and Iatrogenic Kaposi sarcoma. Symptoms depend on specific organ involvement. Mucosal lesions appear as bluish to violaceous macules, plaques, and tumors. GI lesions can bleed, sometimes extensively, but usually are asymptomatic. Diagnosis of Kaposi sarcoma is confirmed by punch biopsy. Surgical excision, cryotherapy, electrocoagulation, intralesional chemotherapy, or possibly topical imiquimod are recommended for superficial lesions and for local radiation therapy and chemotherapy for multiple lesions, diffuse involvement, or lymph node disease.
'Kaposi’s sarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kaposi’s sarcoma pipeline landscape is provided which includes the disease overview and Kaposi’s sarcoma treatment guidelines. The assessment part of the report embraces, in depth Kaposi’s sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kaposi’s sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Kaposi’s sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Kaposi’s sarcoma Emerging Drugs
Further product details are provided in the report..
Kaposi’s sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Kaposi’s sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Kaposi’s sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Kaposi’s sarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kaposi’s sarcoma drugs.
Kaposi’s sarcoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Kaposi’s sarcoma – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Kaposi’s sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Kaposi’s sarcoma: Overview
Kaposi sarcoma, also called idiopathic multiple pigmented hemorrhagic sarcoma, rare and usually lethal cancer of the tissues beneath the surface of the skin or of the mucous membranes. The disease can spread to other organs, including the liver, lungs, and intestinal tract. Kaposi sarcoma is characterized by red-purple or blue-brown lesions of the skin, mucous membranes, and other organs. Kaposi sarcoma originates from endothelial cells in response to infection by human herpesvirus type 8 (HHV-8). Immunosuppression (particularly by AIDS and drugs for organ transplant recipients) markedly increases the likelihood of Kaposi sarcoma in HHV-8–infected patients. KS is categorized into the following 4 types: Classic Kaposi sarcoma, AIDS-associated Kaposi sarcoma, Endemic Kaposi sarcoma, and Iatrogenic Kaposi sarcoma. Symptoms depend on specific organ involvement. Mucosal lesions appear as bluish to violaceous macules, plaques, and tumors. GI lesions can bleed, sometimes extensively, but usually are asymptomatic. Diagnosis of Kaposi sarcoma is confirmed by punch biopsy. Surgical excision, cryotherapy, electrocoagulation, intralesional chemotherapy, or possibly topical imiquimod are recommended for superficial lesions and for local radiation therapy and chemotherapy for multiple lesions, diffuse involvement, or lymph node disease.
'Kaposi’s sarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kaposi’s sarcoma pipeline landscape is provided which includes the disease overview and Kaposi’s sarcoma treatment guidelines. The assessment part of the report embraces, in depth Kaposi’s sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kaposi’s sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Kaposi’s sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Kaposi’s sarcoma.
This segment of the Kaposi’s sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Kaposi’s sarcoma Emerging Drugs
- sEphB4-HAS: Vasgene Therapeutics
Further product details are provided in the report..
Kaposi’s sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Kaposi’s sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Kaposi’s sarcoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Kaposi’s sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Kaposi’s sarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kaposi’s sarcoma drugs.
Kaposi’s sarcoma Report Insights
- Kaposi’s sarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Kaposi’s sarcoma drugs?
- How many Kaposi’s sarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Kaposi’s sarcoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Kaposi’s sarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Kaposi’s sarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Kaposi’s sarcoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Kaposi’s sarcoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Kaposi’s sarcoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Kaposi’s sarcoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
sEphB4-HAS: Vasgene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical stage products
Comparative Analysis
ALVR108: Allovir
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Kaposi’s sarcoma Key Companies
Kaposi’s sarcoma Key Products
Kaposi’s sarcoma- Unmet Needs
Kaposi’s sarcoma- Market Drivers and Barriers
Kaposi’s sarcoma- Future Perspectives and Conclusion
Kaposi’s sarcoma Analyst Views
Kaposi’s sarcoma Key Companies
Appendix
Executive Summary
Kaposi’s sarcoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Kaposi’s sarcoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Kaposi’s sarcoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Kaposi’s sarcoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
sEphB4-HAS: Vasgene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical stage products
Comparative Analysis
ALVR108: Allovir
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Kaposi’s sarcoma Key Companies
Kaposi’s sarcoma Key Products
Kaposi’s sarcoma- Unmet Needs
Kaposi’s sarcoma- Market Drivers and Barriers
Kaposi’s sarcoma- Future Perspectives and Conclusion
Kaposi’s sarcoma Analyst Views
Kaposi’s sarcoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Kaposi’s sarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Kaposi’s sarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Kaposi’s sarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Kaposi’s sarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
